Ownership and insider activity for Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.
Price
| Price | $10.84 |
| Market Cap | $263M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2025-02-18 | Drugs Made In America Acquisition LLC | P-Purchase | 30,000 | |
| 2025-02-18 | Drugs Made In America Acquisition LLC | P-Purchase | 30,000 | |
| 2025-02-18 | Stockwell Lynn | P-Purchase | 30,000 | |
| 2025-02-18 | Stockwell Lynn | P-Purchase | 30,000 | |
| 2025-01-29 | Drugs Made In America Acquisition LLC | P-Purchase | 400,000 | |
| 2025-01-29 | Drugs Made In America Acquisition LLC | J-Other | 400,000 | |
| 2025-01-29 | Drugs Made In America Acquisition LLC | S-Sale | 5,698,363 | $8.5M |
| 2025-01-29 | Drugs Made In America Acquisition LLC | P-Purchase | 400,000 | |
| 2025-01-29 | Stockwell Lynn | J-Other | 400,000 | |
| 2025-01-29 | Stockwell Lynn | S-Sale | 5,698,363 | $8.5M |
Balance Sheet (10y)
| Year | 2024 | 2025 |
|---|---|---|
| Cash & Equivalents | $1351 | $6137 |
| Short-term Investments | 0 | 0 |
| Receivables | 0 | 0 |
| Inventory | 0 | 0 |
| Total Current Assets | $4991 | $12191 |
| Property, Plant & Equipment | 0 | 0 |
| Goodwill | 0 | 0 |
| Intangible Assets | 0 | 0 |
| Total Assets | $551 | $239.9M |
| Accounts Payable | 0 | $222184 |
| Short-term Debt | $662 | 0 |
| Total Current Liabilities | $796 | $376172 |
| Long-term Debt | 0 | 0 |
| Total Liabilities | $796 | $7.3M |
| Retained Earnings | -$279 | -$7.3M |
| Total Equity | -$244 | $232.6M |
| Total Debt | $662 | 0 |
| Net Debt | -$689 | -$6137 |
| Working Capital | $4195 | -$363981 |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 0.02 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 17.88 |
Profitability
| Return on Equity | 2.92% |
| Return on Invested Capital | -1.82% |
| Return on Assets | 4.15% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALF · LOKV · MLAC · OYSE · RTAC · SIMA · TACH
Explore sector: Financial Services · Shell Companies
More sections of DMAA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks